New treatment protocol including lympholytic and antiretroviral drugs to inhibit murine AIDS

Journal of Acquired Immune Deficiency Syndromes

Volumn 23, Issue 2, 2000, Pages 107-113

  Fraternale, A ^a   Tonelli, A ^a   Casabianca, A ^a   Chiarantini, L ^a   Schiavano, G F ^a   Celeste, A G ^a   Magnani, M ^a  

^a UNIVERSITY OF URBINO   (Italy)

Author keywords

2 Fluoro ara AMP (fludarabine); AZT; Murine retrovirus induced immunodeficiency (MAIDS)

Indexed keywords

FLUDARABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; ERADICATION THERAPY; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0034144120     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200002010-00001     Document Type: Article

References (27)

1. Palella FJ, Delaney KM, Moorman AC. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
2. Meltzer MS, Gendelman HE. Mononuclear phagocytes as targets, tissue reservoirs, and immunoregulatory cells in human immunodeficiency virus disease. Curr Top Microbiol Immunol 1992;181: 239-63.
3. Mosier D, Sieburg H. Macrophage-tropic HIV: critical for AIDS pathogenesis? Immunol Today 1994;15:332-9.
4. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoir and total body viral load in HIV-1 infection. Nature 1997;187:183-7.
5. Embretson J, Zupancic M, Ribas JL, et al. Massive convert infection of helper T lymphocytes and macrophages by HIV during he incubation period of AIDS. Nature 1993;362:359-62.
6. Pantaleo G, Graziosi C, Demerest J, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993;362:355-8.
7. Garcia-Blanco MA, Cullen BR. Mononuclear basis of latency in pathogenic human viruses. Science 1991;254:815-20.
8. Chun TW, Finzi D, Margolick J, Chadwick K, Schwartz D, Siliciano RF. In vivo fate of HIV-1-infected T cells: quantitative analysis of transition to stable latency. Nat Med 1995;1:1284-90.
9. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999;5:512-7.
10. Harrigan PR, Whaley M, Montaner JS. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS 1999;13:59-62.
11. Jolicoeur P. Murine acquired immunodeficiency syndrome (MAIDS): an animal model to study the AIDS pathogenesis. FASEB J 1991;65:4332-41.
12. Morse HC III, Chattopadhyay SK, Makino M, Fredrickson TN, Hugin AW, Hartley JW. Retrovirus-induced immunodeficiency in the mouse: MAIDS as a model for AIDS. AIDS 1992;6:607-21.
13. Fraternale A, Casabianca A, Tonelli A, et al. Inhibition of murine AIDS by alternate administration of azidothymidine and fludarabine monophosphate. JAIDS J Acquir Immune Defic Syndr 2000 (in press).
14. Mosier DE, Yetter RA, Morse HC III. Functional T lymphocytes are required for a murine retrovirus-induced immunodeficiency disease (MAIDS). J Exp Med 1987;165:1737-42.
15. Fraternale A, Tonelli A, Casabianca A, et al. Role of macrophage protection in the development of murine AIDS. JAIDS J Acquir Immune Defic Syndr 1999;21:81-9.
16. Casabianca A, Vallanti G, Magnani M. Competitive PCR for quantification of BM5d proviral DNA in mice with AIDS. J Clin Microbiol 1998;36:2371-4.
17. Rossi L, Brandi G, Schiavano GF, Chiarantini L, Albano A, Magnani M. In vitro and in vivo toxicity of 2′, 3′-dideoxycytidine in mice. Chem Biol Inter 1992;85:255-63.
18. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. N Engl J Med 1996;334:1011-8.
19. Gulick RM, Mellors JW, Havbir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
20. Lillo FB, Ciuffreda D, Veglia F, et al. Viral load and burden modification following early antiretroviral therapy of primary HIV-1 infection. AIDS 1999;13:791-6.
21. Schrager LK, D'Sonza MP. Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA 1998;280:67-71.
22. + T cells and undetectable plasma virus load. J Infect Dis 1999;180:56-60.
23. + T cells in HIV-1-infecled patients receiving highly active anti-retroviral therapy. Nat Med 1999;5:651-5.
24. Zanussi S, Simonelli C, Bortolin MT, et al. Immunological changes in peripheral blood and in lymphoid tissue after treatment of HIV-infected subjects with highly active anti-retroviral therapy (HAART) or HAART+IL-2. Clin Exp Immunol 1999;116:486-92.
25. Chun HG, Leyland-Jones B, Cheson BD. Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies. J Clin Oncol 1991;9:175-88.
26. Keating MJ, Kantarjian H, O'Brien S, Koller C, Talpaz M, et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1989;74:19-25.
27. Consoli U, El-Tounsi I, Sandoval A, et al. Differential induction of apoptosis by Fludarabine monophosphate in leukemic B and normal T cells in Chronic Lymphocytic Leukemia. Blood 1998;91: 1742-8.